Merit E. Cudkowicz, MD
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Merit E. Cudkowicz, MD sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
Merit E. Cudkowicz, MD: 8 sponsored US clinical trials, 1 recruiting.
Merit E. Cudkowicz, MD sponsors 8 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 7 completed. 0 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Amyotrophic Lateral Sclerosis, with 1 trials.
Upper-quartile sponsor footprint
Merit E. Cudkowicz, MD sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
HEALEY ALS Platform Trial - Master Protocol
NCT04297683
HEALEY ALS Platform Trial - Regimen G DNL343
NCT05842941
HEALEY ALS Platform Trial - Regimen F ABBV-CLS-7262
NCT05740813
HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose
NCT05136885
HEALEY ALS Platform Trial - Regimen D Pridopidine
NCT04615923
HEALEY ALS Platform Trial - Regimen C CNM-Au8
NCT04414345
HEALEY ALS Platform Trial - Regimen A Zilucoplan
NCT04436497
HEALEY ALS Platform Trial - Regimen B Verdiperstat
NCT04436510
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 8 |
Therapeutic Areas
What is open in the Merit E. Cudkowicz, MD pipeline
1 recruiting of 8 indexed (13% open); 7 completed (88%).
Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).
Top condition: Amyotrophic Lateral Sclerosis (1 trial), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Merit E. Cudkowicz, MD: open-pipeline peers nationwide
Peers matched on 8 registered trials and 13% open enrollment, not the therapeutic-area sidebar.
Merit E. Cudkowicz, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors near 13% open enrollment (± trial volume)
- Addario Lung Cancer Medical Institute · 13% recruiting · 8 trials
- American University · 13% recruiting · 16 trials
- Annexon · 13% recruiting · 8 trials
- Ansun Biopharma · 13% recruiting · 8 trials
Related
What to do with this Merit E. Cudkowicz, MD page
8 registered trials is a research-attention snapshot, not an endorsement of Merit E. Cudkowicz, MD or any single study.
- 1 of Merit E. Cudkowicz, MD's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Amyotrophic Lateral Sclerosis is the condition Merit E. Cudkowicz, MD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Amyotrophic Lateral Sclerosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Merit E. Cudkowicz, MD pipeline card: 8 registered trials from official public datasets.Report a data error.